{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:17:16Z","timestamp":1759961836453,"version":"3.38.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/fpc.0b013e328349daba","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T18:34:28Z","timestamp":1317753268000},"page":"694-700","source":"Crossref","is-referenced-by-count":7,"title":["Aminoglycoside-induced suppression of CYP2C19*3 premature stop codon"],"prefix":"10.1097","volume":"21","author":[{"given":"Mateus","family":"Fuchshuber-Moraes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Sampaio Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rimmbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Rosskopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Alex Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Suarez-Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210214","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenomicsgenomics of human cytochromes P450 involved in drug biotransformation.","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"R2-2-20210214","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism.","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R4-2-20210214","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.","volume":"46","author":"De Morais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R5-2-20210214","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/147323001003800430","article-title":"Relationship between the acid-inhibitory effect of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.","volume":"38","author":"Furuta","year":"2010","journal-title":"J Int Med Res"},{"key":"R6-2-20210214","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"R7-2-20210214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","article-title":"CYP2C19 variation and citalopram response.","volume":"21","author":"Mrazek","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R8-2-20210214","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-004-0890-5","article-title":"Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.","volume":"61","author":"Bravo-Villalta","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-2-20210214","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/157016005774913149","article-title":"Pharmacological suppression of premature stop mutations that cause genetic diseases.","volume":"3","author":"Keeling","year":"2005","journal-title":"Curr Pharmacogenomics"},{"key":"R10-2-20210214","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00109-001-0317-z","article-title":"Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.","volume":"80","author":"Keeling","year":"2002","journal-title":"J Mol Med"},{"key":"R11-2-20210214","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr-mouse carrying a human CFTR-G542X transgene.","volume":"80","author":"Du","year":"2002","journal-title":"J Mol Med"},{"key":"R12-2-20210214","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"key":"R13-2-20210214","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1741-7015-5-5","article-title":"In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.","volume":"5","author":"Sermet-Gaudelus","year":"2007","journal-title":"BMC Med"},{"key":"R14-2-20210214","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.","volume":"67","author":"Malik","year":"2010","journal-title":"Ann Neurol"},{"key":"R16-2-20210214","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmb.2004.03.012","article-title":"Alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.","volume":"338","author":"Hein","year":"2004","journal-title":"J Mol Biol"},{"key":"R17-2-20210214","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-1119(89)90358-2","article-title":"Site-directed mutagenesis by overlap extension using the polymerase chain reaction.","volume":"77","author":"Ho","year":"1989","journal-title":"Gene"},{"key":"R18-2-20210214","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/dmd.32.7.699","article-title":"Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes.","volume":"32","author":"Donato","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R19-2-20210214","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/hmg\/ddp030","article-title":"Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo.","volume":"18","author":"Heier","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R20-2-20210214","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jmb.2005.03.025","article-title":"Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough.","volume":"348","author":"Salas-Marco","year":"2005","journal-title":"J Mol Biol"},{"key":"R21-2-20210214","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1017\/S1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in mammalian translation system.","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"R22-2-20210214","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/hmg\/ddh105","article-title":"Aminoglycoside-mediated rescue of a disease causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo.","volume":"13","author":"Sangkuhl","year":"2004","journal-title":"Hum Mol Genet"},{"key":"R23-2-20210214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(03)00050-2","article-title":"Glutamine is incorporated at the nonsense codons UAG and UAA in a suppressor-free Escherichia coli strain.","volume":"1627","author":"Nilsson","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"R25-2-20210214","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1021\/jm801640k","article-title":"Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.","volume":"52","author":"Nudelman","year":"2009","journal-title":"J Med Chem"},{"key":"R26-2-20210214","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations.","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-201111000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:43:02Z","timestamp":1741783382000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201111000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328349daba","relation":{},"ISSN":["1744-6872"],"issn-type":[{"type":"print","value":"1744-6872"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}